BTA 0.00% 57.0¢ biota holdings limited

hrv patents

  1. dma
    4,618 Posts.
    2 HRV Patents dated 28th June, 2007.

    This is Biota,s HRV Patents.

    Human rhinovirus Otherwise healthy adults infected with HRV suffer minor symptoms such as a runny or blocked nose, sneezing, a sore throat, a dry cough, red eyes and a general feeling of tiredness, usually recover within days or weeks. However the virus can be a serious problem for some segments of the population such as infants and the frail elderly. In the United States, 75% of common colds in children under five years are medically attended.

    Whilst common and generally self limiting, HRV is a major cause of hospitalisation for patients with underlying respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), where HRV can aggravate their existing disease.

    Estimates suggest that HRV is linked to about 70% of all asthma exacerbations and more than 50% of the hospitalised cases. Studies also suggest that more than 35% of acute COPD patients requiring hospitalisation, are associated with respiratory viruses, including rhinovirus.

    There is currently no effective treatment for HRV. Therefore, if successful, Biota's HRV compound will address an important and unmet medical need.

    Biota's solution

    Rhinoviruses access nasal cells by attaching to a receptor on the cell surface. Canyon-like clefts on the surface of the virus attach to the receptor and allow the virus to infect the cell. Biota is developing antiviral compounds which are designed to bind to these evolutionarily conserved clefts of HRV's capsid shell and interfere with virus attachment to the targeted cell's receptor.

    Biota completed a Phase I (single & multi-dose) clinical trial of its HRV drug in 2007.

    May need you to interpret TJW.

    Cheers dma
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.